Qualigen Therapeutics (QLGN) News Today → The most important AI company you've never heard of (From Manward Press) (Ad) Free QLGN Stock Alerts $0.31 +0.02 (+6.97%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 16, 2024 | markets.businessinsider.comQualigen Announced An Agreement With Marizyme To Commercialize DuraGraftApril 16, 2024 | finance.yahoo.comMarizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™April 12, 2024 | uk.investing.comQualigen presents preclinical novel cancer inhibitors at AACR 2024April 10, 2024 | globenewswire.comQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingApril 9, 2024 | globenewswire.comQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingFebruary 22, 2024 | morningstar.comQualigen Therapeutics Inc Ordinary Shares QLGNFebruary 7, 2024 | uk.investing.comQualigen Therapeutics Inc (QLGN)November 27, 2023 | finance.yahoo.comQLGN: Dosing Begins in Phase 1 Trial of QN-302…November 14, 2023 | finance.yahoo.comQualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023November 7, 2023 | finance.yahoo.comQualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsOctober 23, 2023 | finance.yahoo.comPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerSeptember 27, 2023 | finance.yahoo.comQualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023September 2, 2023 | ca.finance.yahoo.comQualigen Therapeutics Inc (7R9.DU)August 30, 2023 | finance.yahoo.comQLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23…August 17, 2023 | finance.yahoo.comQualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsAugust 15, 2023 | msn.comQualigen Therapeutics GAAP EPS of -$0.69, revenue of $1.62MAugust 15, 2023 | finance.yahoo.comQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023August 1, 2023 | finance.yahoo.comQualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsJuly 24, 2023 | finance.yahoo.comQualigen Therapeutics Divests FastPack® Diagnostics BusinessJune 14, 2023 | finance.yahoo.comQLGN: Data for Pan-RAS Platform Presented at ASCO…June 6, 2023 | technews.tmcnet.comPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingJune 5, 2023 | finance.yahoo.comPoster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingMay 18, 2023 | seekingalpha.comQualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61MMay 16, 2023 | finance.yahoo.comQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023May 12, 2023 | finance.yahoo.comQLGN: IND for QN-302 to be Submitted in Mid-2023…May 2, 2023 | finance.yahoo.comQualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateMay 2, 2023 | finance.yahoo.comQualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingApril 21, 2023 | finance.yahoo.comQualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingApril 18, 2023 | finance.yahoo.comQualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FLApril 18, 2023 | finance.yahoo.comQualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FLMarch 21, 2023 | finanznachrichten.deQualigen Therapeutics, Inc.: Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark OfficeMarch 21, 2023 | finance.yahoo.comComposition of Matter Patent for QN-302 Granted by United States Patent and Trademark OfficeMarch 15, 2023 | finance.yahoo.comQualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023March 9, 2023 | finance.yahoo.comQualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS ConferenceMarch 8, 2023 | finance.yahoo.comData on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal MoleculesFebruary 1, 2023 | finance.yahoo.comQualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to StockholdersJanuary 24, 2023 | finance.yahoo.comQualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302January 23, 2023 | finance.yahoo.comQualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate CommunicationsJanuary 10, 2023 | marketwatch.comQualigen Therapeutics' QN-302 Receives FDA's Orphan Drug DesignationJanuary 10, 2023 | finance.yahoo.comQualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic CancerJanuary 5, 2023 | finance.yahoo.comQualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic PlatformDecember 13, 2022 | finanznachrichten.deQualigen Therapeutics, Inc.: Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RuleDecember 12, 2022 | technews.tmcnet.comQualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RuleDecember 7, 2022 | finance.yahoo.comQualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid TumorsDecember 1, 2022 | finance.yahoo.comQLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor…November 22, 2022 | finance.yahoo.comQualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock SplitNovember 17, 2022 | finance.yahoo.comQualigen Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 15, 2022 | finance.yahoo.comQualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 21, 2022 | seekingalpha.comQLGN Qualigen Therapeutics, Inc.October 19, 2022 | finance.yahoo.comQualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Wall Street legend who predicted 2021 tech crash issues new warning (Ad)People around the world follow 50-year Wall Street veteran Marc Chaikin for his surprisingly accurate stock predictions. And he just issued an urgent WARNING for some of the most popular stocks in U.S. history. Watch his stock warning right here, 100% free of charge QLGN Media Mentions By Week QLGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QLGN News Sentiment▼1.890.55▲Average Medical News Sentiment QLGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QLGN Articles This Week▼10▲QLGN Articles Average Week Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALLR News Today PRFX News Today ATNF News Today PXMD News Today INM News Today CMND News Today BPTH News Today GLMD News Today NBSE News Today DRMA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QLGN) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.